Hidalgo-Tenorio, CarmenCortés, Luis LópezGutiérrez, AliciaSantos, JesúsOmar, MohamedGálvez, CarmenSequera, SergioJesús, Samantha Eisabeth DeTéllez, FrancisoFernández, ElisaGarcía, CoralPasquau, Juan2023-01-252023-01-252019http://hdl.handle.net/10668/14378Dolutegravir (DTG) has shown effectiveness in combination with rilpivirine in with experience of antiretroviral therapy (ART) and with 3TC in naïve patients (GEMINI trial). The main objectives of this real-life study were to analyze the effectiveness and safety of 3TC plus DTG in virologically suppressed HIV-1 patients and to conduct a pharmacoeconomic analysis.We conducted an observational, retrospective and multicenter study of HIV+ patients pretreated for at least 6 months with ART that was then simplified to 3TC + DTG for any reason. We gathered data on viral loads (VLs) during exposure to the DT, calculating the rate with VLenAttribution-NonCommercial 4.0 Internationalhttp://creativecommons.org/licenses/by-nc/4.0/AdultAnti-HIV AgentsCD4 Lymphocyte CountCost-Benefit AnalysisDrug Therapy, CombinationEconomics, PharmaceuticalFees, PharmaceuticalFemaleHIV InfectionsHIV-1Heterocyclic Compounds, 3-RingHumansLamivudineMaleMiddle AgedOxazinesPiperazinesPyridonesRetrospective StudiesViral Loadresearch article31393412open access10.1097/MD.00000000000168131536-5964PMC6708975https://doi.org/10.1097/md.0000000000016813https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6708975/pdf